share_log
Reuters ·  May 5 14:10
Tar-210 Results Show 90% Recurrence-Free Survival and 90% Complete Response in Patients With High-Risk and Intermediate-Risk Non-Muscle-Invasive Bladder Cancer, Respectively
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment